Side-by-side · Research reference
FOXO4-DRIvsPancragen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED12/45 cited
BAnimal-StrongHUMAN-REVIEWED23/39 cited
FOXO4-DRI
Senolytic Peptide · D-Retro-Inverso
SQ · Animal models only
01Mechanism of Action
Parameter
FOXO4-DRI
Pancragen
Primary target
FOXO4-p53 protein complex in senescent cellsBourgeois 2025Tripathi 2021
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Pathway
FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Downstream effect
Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021Alameen 2026
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Feedback intact?
—
Yes — preserves physiological glucose-insulin response
Origin
D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Antibody development
—
—
02Dosage Protocols
Parameter
FOXO4-DRI
Pancragen
Animal dose (mouse)
5 mg/kg
SQ injection, aged mouse model (testosterone restoration).
—
Frequency (animal)
Variable — single or intermittent dosing
Protocol-dependent; no standardised regimen.
—
Human equivalent (theoretical)
~0.4 mg/kg (28 mg / 70 kg adult)
Extrapolated using allometric scaling; no clinical validation.
—
Evidence basis
Animal / mechanistic
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Duration
Weeks to months (animal studies)
Senescent cell clearance observed within weeks.
—
Clinical status
No human trials completed
—
Primate dose (rhesus macaque)
—
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
Diabetes model
—
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
04Side Effects & Safety
Parameter
FOXO4-DRI
Pancragen
Pulmonary hypertension risk
Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023
—
Context-dependent toxicity
Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023
—
Off-target apoptosis
Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)
—
Immune perturbation
Senescent cells contribute to immune surveillance; clearance effects unknown
—
Human safety unknown
No clinical trials — toxicity profile in humans not established
—
Reported adverse events
—
None documented in primate studies
Human safety data
—
No published human trials; clinical use limited to Russian gerontology protocols
Absolute Contraindications
FOXO4-DRI
- ·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
- ·Pregnancy / lactation (no safety data)
Pancragen
—Relative Contraindications
FOXO4-DRI
- ·Active malignancy (senescence as tumour suppressor mechanism)
- ·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
05Administration Protocol
Parameter
FOXO4-DRI
Pancragen
1. Pre-clinical route
Subcutaneous injection used in rodent models. No human administration protocol exists.
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
2. Reconstitution (animal)
Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
3. Dosing schedule
Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.
No specific timing constraints documented. Administered once daily in primate protocols.
4. Clinical development status
No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
5. Safety monitoring (proposed)
Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.
—